MLchartDataset catalogue

doxorubicin-HPMA conjugate

Term · Oncology and biomedicine · MLC-T-ONC-013158

A copolymer conjugate of the antineoplastic anthracycline doxorubicin and the water-soluble polymer N-(2-hydroxypropyl) methacrylamide (HPMA). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipid. HPMA conjugation enhances the permeability and retention of this agent within the tumor vasculature. Poorly cleared by the lymphatic system, this formulation undergoes increased cleavage by tumor cell lysosomal proteinases, resulting in increased, sustained intracellular concentrations of free doxorubicin. Compared to other doxorubicin-containing formulations, this formulation may exhibit an improved toxicity profile due to the lower concentrations of free doxorubicin to which non-malignant tissues are exposed.

Table 1. Record
IdentifierMLC-T-ONC-013158
FieldOncology and biomedicine
AbbreviationP(GFLG)-ADR
SynonymsHPMA-doxorubicin; doxorubicin-HPMA; doxorubicin-HPMA copolymer conjugate
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013158",
  "term": "doxorubicin-HPMA conjugate",
  "field": "Oncology and biomedicine",
  "definition": "A copolymer conjugate of the antineoplastic anthracycline doxorubicin and the water-soluble polymer N-(2-hydroxypropyl) methacrylamide (HPMA). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipid. HPMA conjugation enhances the permeability and retention of this agent within the tumor vasculature. Poorly cleared by the lymphatic system, this formulation undergoes increased cleavage by tumor cell lysosomal proteinases, resulting in increased, sustained intracellular concentrations of free doxorubicin. Compared to other doxorubicin-containing formulations, this formulation may exhibit an improved toxicity profile due to the lower concentrations of free doxorubicin to which non-malignant tissues are exposed.",
  "abbreviation": "P(GFLG)-ADR",
  "synonyms": [
    "HPMA-doxorubicin",
    "doxorubicin-HPMA",
    "doxorubicin-HPMA copolymer conjugate"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/doxorubicin-hpma-conjugate/"
}

Record 6,222 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.